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Despite the development of potent RAF/mitogen-
activated protein kinase (MAPK) pathway inhibitors,
only a fraction of BRAF-mutant patients benefit
from treatment with these drugs. Using a combined
chemogenomics and chemoproteomics approach,
we identify drug-induced RAS-RAF-MEK complex
formation in a subset of BRAF-mutant cancer cells
characterized by primary resistance to vemurafenib.
In these cells, autocrine interleukin-6 (IL-6) secretion
may contribute to the primary resistance phenotype
via induction of JAK/STAT3 and MAPK signaling.
In a subset of cell lines, combined IL-6/MAPK inhi-
bition is able to overcome primary resistance to
BRAF-targeted therapy. Overall, we show that the
signaling plasticity exerted by primary resistant
BRAF-mutant cells is achieved by their ability to
mimic signaling features of oncogenic RAS, a strat-
egy that we term ‘‘oncogene mimicry.’’ This model
may guide future strategies for overcoming primary
resistance observed in these tumors.
INTRODUCTION
Activating mutations in the serine/threonine kinase BRAF are
among the most common genetic lesions across all cancers
and leads to RAS-independent induction of mitogen-activated
protein kinase (MAPK) signaling in these tumors (Bamford
et al., 2004; Davies et al., 2002; Seger and Krebs, 1995). Given
the central role of MAPK signaling for tumor growth of BRAF-
mutant cancers, a multitude of targeted drugs have been devel-
oped. In contrast to KRAS-mutant tumors, in subgroups of
BRAF-mutant patients, MAPK pathway inhibitors such as ve-
murafenib or trametinib have been shown to be clinically active
(Chapman et al., 2011; Falchook et al., 2012; Ja¨nne et al., 2013).
The central paradigm in the development of inhibitors of onco-
genically driven cancers is that patients harboring kinase muta-Celtions are highly likely to benefit from inhibition of the pathway
engaged by these kinases. The efficacy of such a targeted
approach is commonly limited through selection of cells that
are insensitive to the drug (acquired resistance), as observed
for BCR-ABL-positive chronic myeloid leukemia tumors treated
with imatinib (Shah et al., 2004). Despite dramatic responses in
subgroups of melanoma patients, in the case of MAPK pathway
inhibitors, the major clinical challenge is the high rate of BRAF-
mutant tumors that never respond to treatment (primary resis-
tance) (Chapman et al., 2011; Kudchadkar et al., 2012). The
finding that BRAFV600E present in different tissues exhibits dras-
tically different sensitivity to vemurafenib suggests drastically
different wiring diagrams and adds to the complexity of primary
resistance to MAPK pathway inhibition in BRAF-mutant tumors
(Prahallad et al., 2012).
A great deal of recent effort has been expended to understand
the different intrinsic signaling behavior of BRAFV600E cells of
different tissues of origin in response to BRAF inhibitors. Rosen
and colleagues have uncovered a profound relief of upstream
negative feedback upon BRAF inhibition, which explains resis-
tance in melanoma cells (Lito et al., 2012). Other studies identi-
fied the EGFR/HER3 pathway as a source of primary resistance
signaling that may overcome MAPK pathway inhibition in BRAF-
mutant cells (Corcoran et al., 2012; Montero-Conde et al., 2013;
Prahallad et al., 2012). Intrigued by these observations, we initi-
ated an effort to systematically map the signaling differences be-
tween primary resistant and sensitive BRAFV600E-mutant cells
originating from different tissues.
Our approach relied on two complementary mass spectrom-
etry platforms: (1) a kinase inhibitor bead-based affinity purifi-
cation to profile active kinases within the MAPK pathway and
parallel pathways, and (2) a stable isotope labeling with amino
acids in cell culture (SILAC)-based phosphoproteomic analysis
to capture the output of a wide variety of signaling outputs. To
our knowledge, this is themost comprehensive kinase and phos-
phoprotein analysis of the primary resistant state of BRAFV600E-
mutant tumor cells. Our analyses uncover several mechanisms
that buffer the drug-induced blockade of MAPK signaling.
Furthermore, we show that primary resistant cells, in contrast
to the sensitive cells, secrete the cytokine interleukin-6 (IL-6) inl Reports 8, 1037–1048, August 21, 2014 ª2014 The Authors 1037
Figure 1. Primary Resistance to MAPK Inhi-
bition in BRAF-Mutant Cancer
(A) Viability of cell lines transfected with either
BRAF- (white) or CRAF-siRNA (gray) as compared
to control siRNA is displayed. p values (t test)
represent statistical significance, and whiskers of
boxplots represent SD.
(B) Cells transfected with control-, BRAF-, or
CRAF-siRNA were analyzed for BRAF, CRAF, and
actin protein expression.
(C) Hierarchical clustering of compound
(PD325901, ERKi, AZD6244, RO5126766, and
vemurafenib; x axis) activity profiles across
BRAFV600E-mutant cell lines (CRC, colorectal;
MEL, melanoma; TC, thyroid; y axis). Color-coded
bars represent compound activity (red, active;
white, inactive) bars.
(D) Induction of apoptosis (y axis) after 72 hr
treatment with vemurafenib (1 mM), PD325901
(0.1 mM), or ERKi (0.3 mM) is displayed across
BRAFV600E-mutant cells (CRC, colorectal; MEL,
melanoma; TC, thyroid; x axis).
Error bars represent SEM.an autocrine fashion, which may endow cells with the ability to
bypassMAPK pathway inhibition. These findings provide several
mechanisms that contribute to the distinction between sensitive
and primary resistant BRAFV600E-mutant cancer types and their
ability to mimic molecular features of KRAS-mutant cells to
promote resistance signaling. Finally, our results may provide
several rational therapies to combine with MAPK pathway inhib-
itors in order to circumvent primary resistance in subgroups of
BRAFV600E-mutant tumors.
RESULTS
Primary Resistance to MAPK Inhibition Is Uncoupled
from BRAF Dependency
Since sensitivity to MAPK pathway inhibition in BRAF-mutant
cells has been linked to the individual lineage of the tumor, we
first set out to test if BRAF dependency would differ between
BRAF-mutant cells derived from different tissues (Corcoran
et al., 2012; Prahallad et al., 2012). To this end, we depleted
BRAF in A375 (melanoma), COLO-205 (colorectal carcinoma),
and SW1736 and UHTH104 (thyroid carcinoma) BRAFV600E-
mutant cells (Figures 1A and 1B). Knockdown of BRAF, but not
of its close homolog CRAF, led to a significant (p < 0.0001)
reduction of cellular viability in all cells (Figures 1A and 1B).
Next, we assessed the activity of a series of RAF (vemurafenib,
RO5126766), MEK (PD325901, selumetinib), and ERK (A0048-
48) inhibitors in a collection of BRAFV600E-mutant cell lines.
When performing hierarchical clustering of the individual half-
maximal inhibitory concentration values, we identified a striking
difference in the sensitivity of subgroups of BRAF-mutant cells
(Figure 1C) with primarily thyroid cancer cells enriched in the
group of resistant cells (Figure S1A). This differential vulnerability
pattern was also reflected in apoptosis assays performed in cells
treated with vemurafenib, PD325901, or A0048-58 (ERKi) (Fig-
ure 1D). However, short-term pathway inhibition (1 hr) with the in-1038 Cell Reports 8, 1037–1048, August 21, 2014 ª2014 The Authordividual compounds resulted in a similar deactivation of MAPK
signaling effectors (Figure S1B) and a similar perturbation of
the transcriptional output of the pathway (Figure S1C) in sensitive
(A375) and resistant (BCPAP and SW1736) cell lines (Pratilas
et al., 2009). Overall, these data suggest that BRAF dependency,
as determined by small interfering RNA (siRNA) against BRAF,
is conserved in BRAF-mutant cells. However, the dependency
does not correlate with pharmacologic perturbation of the
pathway, as a subset of the BRAF-mutant cells (enriched for thy-
roid carcinoma) displays primary resistance to MAPK pathway
inhibition.
MAPK Inhibition Promotes RAS-RAF-MEK Complex
Formation and MAPK Hyperactivation in Primary
Resistant Cells
Previous studies inBRAF-mutant cancers identified loss of feed-
back inhibition of RAS as a potential source for resistance to
RAF-MAPK inhibition and reactivation of the MAPK pathway
(Corcoran et al., 2012; Montero-Conde et al., 2013). In line with
these studies, we observed induction of RAS activity and subse-
quent restoration of MAPK pathway signaling as measured by
phosphorylation of CRAF and ERK only in MAPK inhibitor-resis-
tant, but not sensitive, cancer cells (Figures 2A and S2A). To test
if activated RAS may be causally linked with MAPK pathway
reactivation, we overexpressed a wild-type KRAS and a mutant
KRASG12C allele in BRAF-mutant sensitive cells and treated
these cells with either PD325901 (Figure 2B) or vemurafenib
(Figure S2B). In all scenarios, short-term treatment (1–3 hr) with
both drugs led to a robust deactivation of MAPK signaling as
measured by phospho-ERK. However, within 24 hr, only cells
expressing KRASG12C, but not KRASWT, were able to restore
phospho-ERK levels (Figures 2B and S2B). These data suggest
that oncogenically activated KRAS canmimic the effects of feed-
back-activated RAS in its ability to override the MAPK inhibitor-
mediated deactivation of ERK. Knockdown of BRAF or KRAS ins
two resistant cells validated the importance of RAS/RAF effector
activation for the induction of primary resistance to MAPK inhibi-
tion (Figures S2C and S2D).
Complex formation of RAF dimers is known to activate MAPK
signaling, and thus we hypothesized that drug-induced RAS
activation might induce formation of RAS-RAF dimers to pro-
mote MAPK pathway reactivation (Rushworth et al., 2006).
Indeed, we found that expression of KRASG12C promotes RAS-
RAF dimer formation without influencing BRAF-CRAF and
BRAF-MEK binding, suggesting that RAS is joining a multimeric
complex (Figure 2C). Since drug-inducedRAS-RAF complex for-
mation might play a role in MAPK pathway reactivation, we as-
sessed whether drug treatment induces the formation of these
complexes in MAPK inhibitor primary resistant BRAF-mutant
cells in immunoprecipitation assays. These analyses revealed
that induction of BRAF-CRAF dimerization correlates with
MAPK pathway reactivation in primary resistant, but not in sen-
sitive, cells (Figure S2E). The formation of CRAF-BRAF hetero-
dimers is paralleled by their recruitment to RAS and binding to
MEK, resulting in the formation of RAS-RAF-MEKmultimers (Fig-
ure S2F). This is in contrast to BRAFV600E-mutant MAPK inhibi-
tor-sensitive cells, where MEK inhibition does not promote
formation of RAS-RAF complexes and does not induce binding
of RAF to MEK (Figure 2D). We observed a similar induction of
RAS-RAF-MEK complex formation in primary resistant cells
treated with either a RAF or an ERK inhibitor (Figure 2E). These
data suggest that in primary resistant cells, drug treatment in-
duces a time-dependent formation of RAS-RAF-MEK multimers
that ultimately reactivate downstream ERK signaling.
Recent data suggest that the formation of higher-order multi-
mers of RAF kinases might be an important step toward the acti-
vation of MAPK signaling (Nan et al., 2013). To identify these
higher-order multimers and to further substantiate our observa-
tions in immunoprecipitation assays, we developed a small-
molecule affinity probe capable of selectively purifying active
RAF kinase by coupling sorafenib to Sepharose beads (Fig-
ure 2F) (Duncan et al., 2012). Of note, we decided to use sorafe-
nib based on its chemical properties as a tool compound that
can be coupled to Sepharose beads. First, we validated the
capability of sorafenib beads (SFB-B) to capture activation-
induced (via EGF or expression of BRAFV600E-mutant allele)
accumulation of RAF kinases (SFB-B binding) in human embry-
onic kidney 293T cells (Figure S3A). Using this method, we
identified an MEK inhibitor-induced increase in inhibitor-bead
binding affinity for BRAF, CRAF, and also KSR1 in MAPK inhib-
itor-resistant (SW1736), but not in sensitive (SKMEL1), cells
(Figure 2G). Since KSR has been previously described as an
essential component of physiological BRAF signaling transduc-
tion (Brennan et al., 2011), we hypothesized that the drug-
induced KSR1-BRAF binding might play a role in the induction
of primary resistance to MAPK inhibition. Indeed, siRNA-medi-
ated silencing of KSR1 expression significantly reduced MAPK
pathway reactivation (Figure S3B) and cellular viability of MEK
inhibitor-treated cells (SW1736 and UHTH104) (Figures 2H and
S3C). Thus, feedback-induced formation of RAS-RAF-MEK
multimers may also involve KSR1/RAF complexes that add to
the overall phenotype of primary resistance to MAPK inhibition
in BRAF-mutant cells.CelOverriding MAPK Hyperactivation in BRAF-Mutant
Primary Resistant Cells
Encouraged by the utility of a single-inhibitor bead to reveal
differential kinase activation mechanisms, we next developed
a custom-designed multiplexed kinase inhibitor beads (MIB)
library (Duncan et al., 2012; Graves et al., 2013) to systemati-
cally detect drug-induced perturbation of kinase signaling in
MAPK inhibitor primary resistant SW1736 cells at early (1 hr)
and late (24 hr) time points after drug treatment. (Figures
S4A and S4B). Using this enrichment method coupled to
mass spectrometry-based protein analysis (Figure S4C), we
were able to detect 128 unique kinases (Figure 3A; Table
S1). In the group of preferentially enriched kinases after
PD325901 treatment at both time points, we detected canon-
ical MAPK pathway members (MEK2 and ERK1) and five non-
canonical MAPK pathway effectors (MP2K2, M3K2, TAOK2,
M4K5, and TAOK3) (Figures 3A and 3B; Table S1). These re-
sults suggest the formation of activating complexes between
MAPK family members extends beyond those initially identified
using our single-inhibitor bead pull-downs and are part of a
more global signaling adaptation to overcome the initial inhib-
itory effect of the drug.
We speculated that the adaptive range of the increasedMAPK
pathway flux is finite and that high-dose MAPK inhibition may
be able to override this primary resistance mechanism. To test
this hypothesis, we steadily increased the concentration of
PD325901 and measured the ability of the cells to reactivate
MAPK signaling (Figure 3C). As expected, in both sensitive cells
(A375 and SKMEL1), short-term and long-term MEK inhibition
eliminates phospho-ERK, but in primary resistant (SW1736 and
UHTH104) cells, phosphorylation of ERK recovers when cells
are treated with low-dose (0.1 mM) PD325901 (Figure 3C). In
contrast, high-dose (1–10 mM) MEK inhibition prevents recovery
of phospho-ERK levels in these cells (Figure 3C). Interestingly,
high-dose treatment with vemurafenib does not disrupt reactiva-
tion of ERK in these cells, suggesting that the increased pathway
flux is only partially dependent on RAF kinase activity (Fig-
ure S4D). We observed the same pattern of ERK reactivation
following treatment of A375 cells expressing a constitutively
active KRASG12C allele (Figure 3D) that mimics the feedback-
induced effects of primary resistant cells (Figure 2B). The disrup-
tion of MAPK reactivation translates into a dramatic increase
in apoptosis, as observed in primary resistant SW1736 and
UHTH104 cells treated with PD325901, but not with vemurafenib
(Figure 3E).
Consequently, nude mice xenografts generated from primary
resistant SW1736 cells remained responsive to PD325901 in
a dose-dependent manner, as assessed by tumor volume
change over time of treatment (Figure S4E). After 21 days of
treatment with either 2 mg/kg (low-dose) or 5 mg/kg (high-
dose) PD326901, the high-dose-treated mice showed a higher
rate of tumor shrinkage (two out of six) and a significantly (p =
0.017) decreased tumor volume when compared to the low-
dose-treated cohort (Figures 3F and S4E). Thus, we conclude
that in a subset of BRAF-mutant tumors, primary resistance
to MAPK inhibition is primarily driven by an increased flux of
the MAPK signaling that can be overcome by high-dose MEK
inhibition.l Reports 8, 1037–1048, August 21, 2014 ª2014 The Authors 1039
Figure 2. Feedback-Activated RAS Allows Downstream MAPK Pathway Reactivation
(A) Protein levels of cells (sensitive, black; resistant, red) treated with PD325901 (0, 1, 24, and 48 hr) as detected by immunoblotting. RAS-GTP levels were
detected by pull-downs of cellular RAS with glutathione S-transferase-tagged RAF1-RBD.
(B) PD325901-treated sensitive A375 cells transfected with control, FLAG-KRASWT, or FLAG-KRASG12C were assessed for ERK, phospho-ERK, and FLAG
expression. Due to overlapping protein sizes, bands were not detected at the same membrane.
(C)PD325901-treatedA375cells transfectedwith control, FLAG-KRASWT, or FLAG-KRASG12Cwere assessed formultimersbinding toBRAF in immunoprecipitation
assays and for ERK, phospho-ERK, and FLAG expression by immunoblotting. Due to overlapping protein sizes, bands were not detected at the same membrane.
(D and E) Sensitive A375 (black) and resistant SW1736 (red) cells treated with (D) PD325901 and (E) vemurafenib or the ERK inhibitor ERKi were assessed for
multimers binding to BRAF (upper panel) or RAS (lower panel) in immunoprecipitation assays.
(legend continued on next page)
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Systematic Mapping of Adaptation Signaling Reveals
Mediators of Primary Resistance
TheMIB analysis revealed the set of kinases activated in inhibitor
resistant cells. To capture the downstream consequences of
kinase reactivation occurring in primary resistant MAPK
pathway-reactivated cells, we conducted a SILAC-based map-
ping of cellular phosphopeptides in SW1736 cells treated with
the MEK inhibitor PD325901 over time (0, 1, and 24 hr) (Fig-
ure 4A). We identified 3,481 unique phosphopeptides from
1,396 unique proteins (Table S2). Not surprisingly, the abun-
dance of many phosphopeptides decreased after kinase inhibi-
tion (Figure 4B). Gene Ontology (GO)-term analysis showed that
proteins phosphorylated within 24 hr are significantly enriched
in the category of ‘‘negative regulation of gene expression’’
(SG1, immediate increase) and ‘‘negative regulation of macro-
molecule biosynthetic process’’ (SG2, delayed increase) (Fig-
ure 4B; Table S3). Phosphoproteins decreasing in abundance
within 24 hr of MEK inhibitor treatment were primarily involved
in regulation of the cell cycle (SG3, delayed decrease) and
DNA replication (SG4, immediate decrease) (Figure 4B; Table
S3). In line with previous reports, we found increased phosphor-
ylation of two receptor tyrosine kinases, ERBB3 and MET (SG1),
in the MEK inhibitor-treated SW1736 cells (Figure 4B) (Montero-
Conde et al., 2013; Prahallad et al., 2012). Receptor tyrosine
kinase (RTK) arrays confirmed MEK inhibitor-induced phos-
phorylation of not only ERBB3 and MET but also additional
RTKs such as EGFR or AXL in resistant (SW1736 and BCPAP),
but not in sensitive (A375), cells (Figure 4C). However, we did
not observe an increased expression of ERBB3 and EGFR or
their respective ligands EGF and NRG1 upon MAPK inhibition
(Figure S5A). Interestingly, the treatment with the MET inhibitor
crizotinib or the HER2 inhibitor lapatinib (SW1736 and BCPAP)
failed to prevent MEK inhibitor-induced reactivation of ERK
phosphorylation (Figure S5B). Furthermore, the combination of
lapatinib and PD325901 had only a minor effect on the induction
of apoptosis in primary resistant cells (Figure S5C). These data
suggest that the feedback-induced RTK phosphorylation
pattern is not uniform across resistant cells and that inhibition
of single nodes of RTK signaling may not be sufficient to pre-
vent feedback-induced MAPK reactivation in BRAF-mutant
cancer.
We next focused on the group of proteins found to be phos-
phorylated upon long-term inhibitor treatment (SG2). One of
the top-scoring targets of feedback-induced phosphorylation
encodes for the nuclear interacting partner of ALK (NIPA) (Fig-
ure 4B; Table S2) (Ouyang et al., 2003). In MEK inhibitor-treated
SW1736 cells, we identified robust induction of Ser354 phos-
phorylation, a site that has been identified to be phosphorylated
by ERK2. This protein is known to play a role in the regulation of
the cell cycle and antiapoptotic signaling (Bassermann et al.,
2005; Illert et al., 2012; Ouyang et al., 2003). As expected,
MEK inhibition in sensitive A375 cells led to dephosphorylation(F) Schematic presentation of a sorafenib-based (SFB-B) inhibitor beads.
(G) Accumulation of BRAF, CRAF, and KSR1 was assessed in SKMEL1 (sensitiv
beads in pull-down assays. BRAF, CRAF, and KSR1 were assessed in whole-ce
(H) SW1736 (red, resistant; left panel) cells transfected with control- or KSR1-targ
viability. Error bars represent SEM.
Celof NIPA at Ser354 (Figure 4D). However, in primary resistant
SW1736 cells, we observed sustained NIPA activation (Fig-
ure 4D). Knockdown of NIPA expression via siRNA in SW1736
cells did not affect feedback-induced phosphorylation of ERK
(Figure 4E), but NIPA depletion partially enhanced the effects
of PD325901 in primary resistant SW1736 cells (Figure 4F).
These data indicate that mapping of global signaling adaptation
in BRAF-mutant cells that have a primary resistance to MAPK
inhibition can provide insights into the spectrum of mechanisms
that together may render targeted drugs ineffective in these
tumors.
Autocrine IL-6 Secretion Defines a Subgroup of Primary
Resistant BRAF-Mutant Cells
To further explore the signaling fingerprint of primary resistant
SW1736 cells, we focused on the delayed induction of phos-
phorylation of signal transducer and activator of transcription 3
(STAT3) at Tyr705 (Table S2). Of note, the activation pattern of
STAT3 identified in the SILAC assay (Figure 4B) corresponds
to the delayed enrichment of JAK3 binding in the MIB assays
(Figure 3A), suggesting that the time-dependent reactivation of
JAK/STAT signaling is a conserved response to MEK inhibition
in these cells. Consistently, MEK inhibition led to increased
phosphorylation of STAT3 in two primary resistant cells (BCPAP
andSW1736), but not in sensitive A375 cells (Figure 5A). Interest-
ingly, the induction of phosphorylation of STAT3 was only
partially dependent on treatment of cells with PD325901-con-
taining media, as treatment with fresh media containing DMSO
also led to increased phosphorylation of STAT3 in the resistant
cell lines (Figure 5A). Because cytokines such as IL-6 are known
activators of STAT3 signaling, we hypothesized that an autocrine
loop might be responsible for the time-dependent activation of
JAK/STAT signaling (Heinrich et al., 2003). Indeed, we found
that over time, increasing IL-6 levels can be detected in the
supernatant of resistant cells (BCPAP and SW1736), but not
sensitive (A375) cells (Figure 5B). We next assessed IL-6 secre-
tion in all of the initially screened BRAF-mutant cells and found a
remarkable positive correlation between IL-6 levels and resis-
tance to MAPK inhibitors (Figure 5C). In cytokine arrays, we
were able to confirm that IL-6 and CCL5 are secreted at high
levels in primary resistant cells (BCPAP and SW1736) when
compared to MAPK inhibitor-sensitive A375 cells (Figure 5D).
Interestingly, all cells displayed high levels of the IL-6 receptor
as measured in fluorescence-activated cell sorting (FACS)-
based assays (Figure 5E).
We next asked whether IL-6 might induce resistance in
MAPK inhibitor-sensitive A375 cells. The addition of IL-6 into
media of A375 cells significantly (p < 0.0001 5 ng/ml; p <
0.0001 25 ng/ml) reduced the induction of apoptosis mediated
by PD325901 in a dose-dependent manner as measured in
FACS assays (Figure 6A) and induced STAT3 and partial ERK
phosphorylation (Figure 6B). These data suggest that autocrinee, black; left panel) and SW1736 (sensitive, red; right panel) cells using SFB-B
ll lysates of the given cells.
eted siRNA treated with either control or PD325901 (48 hr) were assessed for
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Figure 3. High-Dose MEK Inhibition Prevents Reactivation of MAPK in Primary Resistant Cells
(A) Mapping of all identified kinases (n = 128) according to the log2-change of enrichment as compared to control for cells treated either for 1 hr (x axis) or 24 hr
(y axis) with PD325901. Selected proteins in the individual groups (red: SG1, immediate enrichment; gray: SG2, delayed enrichment; blue: SG3, immediate
decrease; green: SG4, delayed decrease) are highlighted.
(B) Fold-change enrichment of selected kinases binding to MIBs (log2-scale) as detected bymass spectrometry in resistant SW1736 cells treated with PD325901
(24 hr). MAPK components are marked in red.
(C) Cells (sensitive, black; resistant, red) were treated with increasing concentrations of PD325901 (1 hr and 24 hr). Cells were either treated for 24 hr (‘‘C’’) or
compound was washed out (‘‘WO’’) with fresh media after 1 hr treatment. ERK and phospho-ERK levels were assessed in immunoblotting assays.
(legend continued on next page)
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IL-6 signaling might play role in the setting of primary resistance
to MAPK inhibition in BRAF-mutant cells. To validate the impor-
tance of IL-6 signaling in primary resistance, we depleted IL-6
in SW1736 and BCPAP cells using siRNA (Figure S6A). Cells
transfected with IL-6-targeted siRNA showed significantly
increased induction of apoptosis (p = 0.007 BCPAP; p = 0.02
SW1736) only in combination with MEK inhibitor treatment (Fig-
ure 6C), and we found reduced reactivation of STAT3 and par-
tial ERK reactivation in both cell lines when compared to control
cells (Figure 6D).
Since clinical JAK inhibitors are available, we tested the
efficacy of JAK inhibition in combination with MAPK inhibition
in primary resistant cells. Indeed, the combined inhibition of
JAK signaling with the pan-JAK inhibitor tofacitinib and MEK
signaling with PD325901 resulted in suppression of STAT3 re-
activation (Figure 6E) and significantly increased the effect of
single-agent MAPK inhibition in two out of three resistant cell
lines (Figures 6F and S6B). Overall, our data demonstrate that
a subset of primary resistant BRAF-mutant cells is defined by
autocrine cytokine signaling that may guide the choice of
combinatorial strategies for the effective treatment of these
tumors.
DISCUSSION
Our chemical proteomics approach to dissect global signaling
networks in BRAF-mutant cells revealed two major mecha-
nisms that contribute to primary resistance: (1) in primary resis-
tant cells, MAPK pathway inhibition can induce RAS-RAF-MEK
complex formation that buffers inhibition of the pathway and
shifts cellular sensitivity to high-dose MEK inhibition; and (2)
autocrine IL-6 secretion and subsequent activation of JAK/
STAT signaling represent an unexpected route to overcome
targeted inhibition of the MAPK pathway. Both strategies
resemble the adaptation mechanisms by which KRAS-mutant
cells escape targeted inhibition of MAPK signaling, and thus
we propose to name this primary resistance concept ‘‘onco-
gene mimicry.’’
Previous studies have implicated paradoxical RAF dimeriza-
tion as a source for primary resistance to RAF inhibitors in
BRAF wild-type cells (Heidorn et al., 2010; Poulikakos et al.,
2010). This model elegantly predicted activated RAS as a po-
tential source for RAF inhibitor resistance in BRAF-mutant cells
(Poulikakos et al., 2010). Our analyses expand this mechanistic
model by revealing that activated RAS facilitates formation of
RAS-RAF-MEK complexes that allow hyperactivation of the
upstream pathway and reactivation of ERK signaling indepen-
dently of direct RAF kinase inhibition. Using kinase inhibitor
beads, we were able to show that in BRAF-mutant cells,(D) A375 cells were transfectedwith FLAG-KRASG12C andwere treated with either
with fresh media after 1 hr treatment. ERK and phospho-ERK levels were assesse
detected at the same membrane.
(E) Induction of apoptosis (y axis) after 72 hr treatment with either PD325901 (0,
SW1736 and UHTH104 cells.
(F) Change of tumor volume form baseline (y axis) for individual xenograft tumors o
(black bars) were measured at day 21. p values indicate the statistical significan
Error bars represent SEM.
CelMAPK inhibition can release negative feedback loops to acti-
vate BRAF, CRAF, KSR, and potentially noncanonical members
of the MAPK pathway. Overall, the resulting perturbation of
RAS/RAF signaling in response to MAPK pathway inhibition in
primary resistant BRAFV600E-mutant cells largely resembles
the paradoxical activation of RAF signaling found in KRAS-
mutant cells (Heidorn et al., 2010; Poulikakos et al., 2010). In
line with previous reports, we identify RTK signaling as a target
of negative feedback loop release (Corcoran et al., 2012;
Montero-Conde et al., 2013). However, our data suggest
that the inhibition of single RTK nodes may not be sufficient
to override primary resistance to MAPK pathway inhibition in
BRAF-mutant tumors.
Furthermore, our results demonstrate that a drug-induced in-
crease in pathway flux can shift the therapeutic window for effec-
tive tumor shrinkage ofBRAF-mutant cancers to high-doseMEK
inhibitor treatment regimens. The feasibility of high-dose MEK
treatment of BRAF-mutant patients is limited by potential toxic-
ities at doses higher than the given maximum tolerated dose;
however, strategies like intermittent high-dose scheduling of tar-
geted drugs have been proven to be effective in other scenarios
(Amin et al., 2010) and may be applicable for subgroups of pri-
mary resistant cancer patients.
Building on previous studies, our data further highlight the
value of chemoproteomic analyses for the dissection of signaling
networks perturbed by highly selective kinase inhibitors (Duncan
et al., 2012; Graves et al., 2013). In a subset of cell lines, we
were able to identify activation of NIPA as well as autocrine IL-
6 signaling as potential mediators of primary resistance to
RAF inhibition in BRAF-mutant cancer. The identification of IL-
6 signaling adds to the list of signaling nodes that can mediate
primary resistance upon exposure to their receptor ligands
(Lito et al., 2012; Wilson et al., 2012). Importantly, IL-6 secretion
has been previously reported to play a role in acquired resistance
to selumetinib in a BRAFV600E-mutant model of childhood astro-
cytoma (Bid et al., 2013). Future studies may be able to clarify
howmuch the lineage determines the ability of the cell to secrete
individual cytokines such as IL-6. Furthermore, autocrine secre-
tion of IL-6 and other cytokines has been reported to play amajor
role in the activation of oncogenic signaling in RAS-dependent
cells (Ancrile et al., 2007; Zhu et al., 2014). Thus, autocrine cyto-
kine secretion may represent a previously underappreciated
source of cancer signaling that adds to the ability of primary
resistant BRAF-mutant cells to phenocopy KRAS-mutant cells
and to overcome targeted MAPK pathway inhibition. It remains
to be determined how IL-6 signaling is connected with the indi-
vidual components of the RAS-RAF pathway and whether inhibi-
tion of its downstream effectors can be effective to resensitize
BRAF-mutant cells to RAF inhibitors.PD325901 or vemurafenib for 24 hr (‘‘C’’) or compoundwaswashed out (‘‘WO’’)
d in immunoblotting assays. Due to overlapping protein sizes, bands were not
1, and 10 mM) or vemurafenib (0, 1, and 10 mM) is displayed for resistant (red)
f SW1736 cells treated with either 2 mg/kg (gray bars) or 5 mg/kg of PD325901
ce between the mean change in tumor volumes.
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Figure 4. Mapping of Global Phosphoproteome Perturbation Reveals Effectors of Primary Resistance in BRAF-Mutant Cells
(A) Graphic overview of the isotope-labeling strategy for SILAC-based detection of phosphoproteome activity.
(B) Mapping of all identified phosphopeptides according to the log2-change of phosphorylation levels as compared to control for cells treated for either 1 hr
(x axis) or 24 hr (y axis) with PD325901. Selected proteins in the individual groups (red, SG1; gray, SG2; blue, SG3; green, SG4) are highlighted. Inlay panel (upper
left corner) shows the top-scoring GO-term annotation for the individual groups.
(C) Sensitive (black; A375) and resistant (red; SW1736, BCPAP) cells were treated with PD325901 (0 and 48 hr), and phosphorylation status of 49 RTKs was
detected using RTK arrays. Selected RTKs are highlighted.
(D) Sensitive (black, A375) and resistant (red, SW1736) cells treated with PD32590 (0, 1, and 24 hr) were analyzed for protein expression of phospho-NIPA, NIPA,
phospho-ERK, and ERK.
(E) SW1736 cells transfected with control- or NIPA-targeted siRNA treated either with control or PD325901 (24 hr) were assessed for expression of phospho-
NIPA, NIPA, ERK, and phospho-ERK.
(F) Viability (y axis) of SW1736 cells treated with either control () or PD325901 for 48 hr (+) transfected with either control (white, dark gray) or NIPA (light gray,
black) is displayed.
Statistical significance (Student’s t test) between the average viability of given cells is displayed as p values, and error bars represent SEM.
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Figure 5. Autocrine IL-6 Signaling Defines a Subset of Primary Resistant BRAF-Mutant Cells
(A) Sensitive (black; A375) and resistant (red; SW1736, BCPAP) cells treated with freshmedia containing either DMSO (0, 1, and 24 hr) or PD32590 (0, 1, and 24 hr)
were analyzed for protein expression of phospho-STAT3, STAT3, phospho-ERK, and ERK.
(B) Supernatants of sensitive (black; A375) and resistant (red; SW1736, BCPAP) cells treatedwith freshmedia containing either DMSO (0, 1, and 24 hr) or PD32590
(0, 1, and 24 hr) were analyzed for IL-6 secretion (y axis) using ELISA assays. Error bars represent SEM.
(C) Analysis of IL-6 secretion (y axis) of BRAFV600E-mutant cells (red, resistant; black sensitive) into media 24 hr after plating. Error bars represent SEM.
(D) Supernatants of sensitive (black; A375) and resistant (red; SW1736, BCPAP) cells were analyzed for 23 distinct cytokines using cytokine arrays. Selected
cytokines and positive controls are highlighted.
(E) Sensitive (black; A375) and resistant (red; BCPAP, SW1736, UHTH104) cells were assessed for expression of the IL-6 receptor in FACS-based assays. Error
bars represent SEM.Overall, we show that the dissection of drug-induced negative
feedback loop networks can provide important insights into the
dynamics of primary resistant signaling in BRAF-mutant cancer.
Future analyses of patient samples may potentially allow trans-
lating these findings into the development of novel therapeutic
strategies to further increase the response rates to RAF inhibitors
in BRAF-mutant patients.
EXPERIMENTAL PROCEDURES
Cell Lines and Reagents
Cell lines were obtained from the ATCC (http://www.atcc.org) or received as a
kind gift from Dr. Fagin (SW1736) or Dr. Nils-Erik Heldin (UHTH104) and were
cultured using either RPMI or Dulbecco’smodified Eagle’s medium cell culture
media, supplemented with 10% fetal bovine serum (FBS). All compounds were
purchased from commercial suppliers or kindly provided by Dr. Pingda Ren
(A0048-58, ERKi). Recombinant IL-6 (Peprotech) was diluted in water and
stored at 80C.
Viability Assays
Cell lines were plated in triplicates into 96-well plates (1,000–2,000 cells/well)
and treated with the given compounds. Viability was determined after 48–72 hr
bymeasuring the ATP-content (CellTiter-Glo, Promega), and the percentage ofCelviable cells as compared to DMSO controls was calculated as described
previously (Sos et al., 2009). Half-maximal inhibitory concentration (EC50)
was assessed using nonlinear curve-fitting algorithms (Prism).
Apoptosis Assays
For detection of apoptosis, the Annexin V-FITC Apoptosis Detection Kit I (BD
Biosciences) was used and analysis was performed as described previously
(Sos et al., 2009). Briefly, cells were treated with the given compound (72 hr)
and stained with Annexin V-FITC and propidium iodide before analysis on
a FACS LSRII (Beckman Coulter). Apoptosis was calculated as the difference
between treated sample and DMSO control. At least 10,000 cells were
measured per sample.
Immunoblotting, Immunoprecipitation, and RTK Arrays
Cells were treated at given conditions and lysed in phosphatase and protease
inhibitor containing lysis buffer (Cell Signaling). Samples were run on SDS-
PAGE gels (Life Sciences). All antibodies are listed in Supplemental Experi-
mental Procedures. For immunoblotting, lysates weremixedwith BRAF (Santa
Cruz, B-7) or Ras antibody (Abcam, EPR3255) and incubated overnight (4C).
Protein G agarose beads were used to capture complex formation, and sam-
ples were subjected to SDS-PAGE. For RTK-array experiments, prewashed
RTK membranes (R&D Systems) were incubated with cell lysates (150–
200 mg protein) and chemiluminescent signals were detected on X-ray films
according to the manufacturer’s instructions.l Reports 8, 1037–1048, August 21, 2014 ª2014 The Authors 1045
Figure 6. IL-6 Secretion Sensitizes Primary Resistant Cells to Combined IL-6/MAPK Pathway Inhibition
(A) Induction of apoptosis after 72 hr treatment with either PD325901 (0.1 mM) alone or PD325901 (0.1mM) in combination with IL-6 (5 ng/ml, 25 ng/ml) is displayed
for A375 cells. Error bars represent SEM.
(B) A375 cells treated (24 hr) either with control (±IL-6, 25 ng/ml) or PD325901 (±IL-6, 25 ng/ml) were assessed for expression of phospho-STAT3, STAT3, ERK,
and phospho-ERK. Due to overlapping protein sizes, bands were not detected at the same membrane.
(C) Induction of apoptosis after 48 hr treatment with either PD325901 (0.1 mM) alone or PD325901 (0.1 mM) ±IL-6 depletion (siRNA; 72 hr) is displayed for SW1736
and BCPAP cells. Error bars represent SEM.
(D) SW1736 and BCPAP cells treated (24 hr) either with control (±IL-6 siRNA) or PD325901 (±IL-6 siRNA) were assessed for expression of phospho-STAT3,
STAT3, ERK, and phospho-ERK. Due to overlapping protein sizes, bands were not detected at the same membrane.
(E) SW1736 cells treated (24 hr) with either control (±1 mM tofacitinib) or PD325901 (±1 mM tofacitinib) were assessed for expression of phospho-STAT3, STAT3,
ERK, and phospho-ERK. Due to overlapping protein sizes, bands were not detected at the same membrane.
(F) EC50 values (EC50 > 10 mM, black; EC50 > 1 mM, gray; EC50 < 1 mM, red) as assessed by viability assays are displayed for the given cell lines treated with
PD325901, tofacitinib, or a combination of both inhibitors (1 mM tofacitinib constant).RNAi and Transient Overexpression
Cells were plated (50%–80% confluency) 24 hr prior to transfection with either
the siRNA construct (Lipofectamine RNAiMAX) or the plasmid (Lipofectamine
LTX). All transfection reagents were diluted in serum-free OPTI-MEM media
according to the manufacturer’s instructions. Codon-optimized pJ603-neo-
KRAS (DNA 2.0) and pcDNA3-BRAF constructs were used for transient
expression experiments.
SILAC-Based Phosphoproteomics Strategy Overview
SILAC labeling, mass spectrometry (MS), and data processing for a single
experiment are described in detail in Supplemental Experimental Procedures.
Briefly, cells were metabolically labeled for seven doubling times in RPMI with
10% dialyzed FBS supplemented with heavy (13C6, 15N2-Lys, 13C6, and
15N4-Arg), medium (2H4-Lys and 13C6-Arg), or light (unlabeled Lys and
Arg) amino acids (Thermo Scientific). After compound treatment, cells were
harvested, washed, and lysed in the presence of phosphatase inhibitors,
and equal amounts of protein were combined and digested overnight with
sequencing grade modified trypsin (Promega). Phosphopeptides were en-
riched by titanium oxide chromatography. MS analysis was performed in an
Orbitrap Velos as described in the supplemental information. Data were
searched against the human subset of the SwissProt database using Protein
Prospector (Clauser et al., 1999), as described in Supplemental Experimental1046 Cell Reports 8, 1037–1048, August 21, 2014 ª2014 The AuthorProcedures. Ratios of peptide peak areas between conditions were calcu-
lated, along with variance for each ratio. Plots of calculated ratios were gener-
ated in ‘‘R.’’
MIB-Based Phosphoproteomics Strategy Overview
Compounds were purchased commercially (dasatinib, crizotinib, staurospor-
ine, SB202190, and lapatinib, Selleck Chemicals; purvalanol B, Tocris;
bisindolylmaleimide X, Enzo Life Sciences). Linkable versions of previously
described compounds were synthesized based on prior methods; VI-16832l
(Daub et al., 2008), Akti-46 (Blake et al., 2010), PP-hydroxyl (Tanaka et al.,
2005), sorafenib (Bankston et al., 2001), and JG-4 (Statsuk et al., 2008); purva-
lanol B was coupled to ether-linked 1,6-diaminohexane Sepharose and all
others to ECH following prior methods, with quenching with acetic acid or
ethanolamine, respectively (Duncan et al., 2012). Kinase enrichment was per-
formed as described previously (Cooper et al., 2013; Duncan et al., 2012). A
detailed description of the phosphoproteomic strategy for MIB data genera-
tion for a single experiment is given in Supplemental Experimental Procedures
(Schilling et al., 2012). Plots of calculated ratios were generated in ‘‘R.’’
Statistical Analysis
All experiments were repeated at least three times unless specified other-
wise. Error bars represent SEM, and p values represent statistical significances
as assessed with a t test implemented in Prism (GraphPad) unless stated
otherwise.
IL-6 ELISA Assays and Cytokine Arrays
Supernatants of cells were collected at the indicated time points, and IL-6 was
detected in coated 96-well plates using IL-6 ELISA kits (eBioscience) following
the manufacturer’s instructions. Cytokine arrays (Raybiotech) were incubated
with cell-free supernatant overnight, and the signal was detected using
chemiluminescent signaling on X-ray film according to the manufacturer’s
instructions.
Xenograft Mouse Models
Female 7- to 9-week-old Nu/Nu mice (Harlan, FoxN1/nude) were inoculated
subcutaneously with 107 SW1736 cells. Mice were monitored according to the
protocol approved by the UCSF Institutional Animal Care and Use Committee.
Each animal received two tumors into the left and right flank. At tumor volumes
of 100–200 mm3, mice orally received PD325901 or vehicle daily. Tumor size
was monitored regularly by measurement of perpendicular diameters by an
external caliper, and tumor size (mm3) was calculated as V = 1/2 (length 3
width2). Animals were monitored for the absence of drug toxicity by measuring
the body weight twice weekly and monitoring the overall activity.
ACCESSION NUMBERS
The raw SILAC data can be accessed via http://prospector2.ucsf.edu/
prospector/cgi-bin/msform.cgi?form=msviewerusing thesearchkeyqqj3gxjzkf.
The rawMIB data can be accessed via http://prospector2.ucsf.edu/prospector/
cgi-bin/msform.cgi?form=msviewer using the search key 4pljxgoury.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2014.07.010.
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